Send the following on WhatsApp
Continue to Chathttps://es.marketscreener.com/cotizacion/accion/NEUROGENE-INC-65218886/noticia/Neurogene-presenta-datos-de-seguridad-favorables-del-ensayo-de-fase-1-2-de-la-terapia-genica-Ngn-40-46648479/?utm_source=whatsapp&utm_medium=social&utm_campaign=share